1. Generics Bulletin
  2. >>Products

Henlius Secures First Overseas Approval For Bevacizumab Biosimilar

Henlius And Local Partner Eurofarma Secured The First Approval In Bolivia

 
• By Adam Zamecnik

Following on a slew of approvals in the past year, Henlius announced the first overseas approval of its Avastin biosimilar in Bolivia where it is partnered with the Brazilian firm Eurofarma.

South America
Dr Reddy's will commercialise Prestige's trastuzumab across Latin America and Southeast Asia • Source: Alamy

Shanghai Henlius Biotech and its local partner Eurofarma have managed to land the very first overseas approval of Henlius’ Avastin (bevacizumab) biosimilar Hanbetai in Bolivia, amplifying the Chinese firm’s presence in Latin America.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Generics Bulletin

US FDA Shows Support For Generic Drug User Fee Goals Amid Cutbacks

 
• By Michael McCaughan

The FDA struck an upbeat tone during its annual Generic Drugs Forum despite an unprecedented period of cutbacks and disruptions and reiterated a desire to continue meeting user fee goals.

Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance

 
• By Dave Wallace

Aeon Biopharma has picked up Revance Therapeutics executive Rob Bancroft to serve as its new CEO as it continues to pursue a biosimilar version of Botox. Meanwhile, Coherus has lost its chief commercial officer, as Viatris, Sandoz and Medicines for Ireland have announced new appointments.

OGD’s Policy Office Cut To Have ‘Profound’ Impact On New Generic Approvals, Warns Former FDA Head Gottlieb

 
• By Urtė Fultinavičiūtė

The elimination of the policy division at the Office of Generic Drugs, tariffs, the Section 232 investigation, and a new executive order to promote lower drug prices seem to both cause and purport to solve the same problem: supply chain disruption.